The adult 21-valent pneumococcal conjugate vaccine (V116) shows strong immune responses and tolerability in vaccine-naive at risk adults.

In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...

Rising Cases of Invasive Pneumococcal Disease in Adults Over 50 Spark Warning Thunder Bay – Health News – The Thunder Bay ...

University of Virginia provides funding as a member of The Conversation US. Autumn brings a chill in the air – and the start of another season of respiratory illnesses, which can be especially hard ...

With vaccine sales on the decline across the industry, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. But in the third quarter, the company recorded encouraging sales ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) is an industry-sponsored (Pfizer) trial with the primary objective of showing the efficacy of a polysaccharide conjugate vaccine ...